Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Trial of Interleukin-2 in Combination With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma

NCT02748564 is registered in ClinicalTrials.gov with Rutgers, The State University of New Jersey as lead sponsor.

NCT NCT02748564
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02748564 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Trial of Interleukin-2 in Combination With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma
Lead sponsor
Rutgers, The State University of New Jersey
Phase
Phase 2
Overall status
Terminated
Start date
March 21, 2017
Completion date
June 5, 2023
Enrollment
10 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic melanoma, stage iii mucosal melanoma of the head and neck, stage iiia skin melanoma, stage iiib skin melanoma, stage iiic skin melanoma, stage iv skin melanoma, stage iva mucosal melanoma of the head and neck, stage ivb mucosal melanoma of the head and neck, stage ivc mucosal melanoma of the head and neck